While purchasing medicine - It is important that you let us know what other medicine you are using.
This is for preventing unwanted drug interactions.


Want to ask us a professional question ? Call us or Connect VIA Skype





Skype Me™! 
 



 
 
 
 

IRINOTECAN INJECTION
Home >> Search Drug By Letter >> Search Drug By Letter: I >> IRINOTECAN INJECTION
Search Drug By Letter : A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 IRINOTECAN INJECTION
 Package(a):
CONCENTRATE FOR INFUSION: 2 ml x 40 mg.
Dosage(a):
Monotherapy (for previously treated patient): 350 mg/m2 as an I.V. infusion over a 30-90 minutes period every 3 weeks.
Combination therapy (for previously untreated patients): 180 mg/m2 once every 2 weeks as an I.V. infusion over a 30-90 minute period, followed by an infusion with folinic acid and 5-fluourouracil. See prescribing information for full details.

Prescribing Restrictions:   
 
Package(b):
CONCENTRATE FOR INFUSION: 5 ml x 100 mg.

Dosage(b):
Monotherapy (for previously treated patient): 350 mg/m2 as an I.V. infusion over a 30-90 minutes period every 3 weeks.
Combination therapy (for previously untreated patients): 180 mg/m2 once every 2 weeks as an I.V. infusion over a 30-90 minute period, followed by an infusion with folinic acid and 5-fluourouracil. See prescribing information for full details.

Prescribing Restrictions:   
 
Package(c):
CONCENTRATE FOR INFUSION: 25 ml x 500 mg.
Dosage(c):
Monotherapy (for previously treated patient): 350 mg/m2 as an I.V. infusion over a 30-90 minutes period every 3 weeks.
Combination therapy (for previously untreated patients): 180 mg/m2 once every 2 weeks as an I.V. infusion over a 30-90 minute period, followed by an infusion with folinic acid and 5-fluourouracil. See prescribing information for full details.

Prescribing Restrictions:   
 

Indications:
Treatment of patients with metastatic colorectal cancer in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease; as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. Treatment of patients with small cell lung cancer. Treatment of patients with gastric cancer.
Contra-Indications:
Chronic inflammatory bowel disease and/or bowel obstruction. Hypersensitivity to irinotecan or any of the excipients. Pregnancy and lactation. Bilirubin >3 times the upper limit of the normal range, severe bone marrow failure, WHO performance status >2, concomitant use with St. John’s Wort.
Special Precautions:
Should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy. See prescribing information for full details.
Side Effects:
See prescribing information for full details.
Drug Interactions:
Neuromuscular blocking agents. CYP3A-inducing anticonvulsant drugs (e.g., rifampicin, carbamazepine, phenobarbital or phenytoin). Consideration should be given to starting or substituting non-enzyme-inducing anticonvulsants at least one week prior to initiation of irinotecan therapy (e.g., ketoconazole) in patients requiring anticonvulsant treatment.